1. The value of concurrent endoscopic ultrasound-guided fine needle aspirates and needle core biopsies in the diagnosis of pancreatic neoplasms.

2. Cytomorphological and immunohistochemical features of pancreatic ductal adenocarcinoma in serous fluids.


5. Pronounced squamous cell contamination in biliary tract cytology: A diagnostic pitfall.

6. The molecular landscape of pancreatic ductal adenocarcinoma.
Sivapalan L, Kocher HM, Ross-Adams H, Chelala C.
Pancreatology. 2022 Nov;22(7):925-936.

7. Integrative transcriptomic analysis identifies a novel gene signature to predict prognosis of pancreatic cancer in different subtypes.

8. Systemic inflammation response index correlates with survival and predicts oncological outcome of resected pancreatic cancer following neoadjuvant chemotherapy.
9. Long-term outcomes of patients with multifocal intraductal papillary mucinous neoplasm following pancreatectomy.


11. Fate of Patients With Intraductal Papillary Mucinous Neoplasms of Pancreas After Resection According to the Pathology and Margin Status: Continuously Increasing Risk of Recurrence Even After Curative Resection Suggesting Necessity of Lifetime Surveillance.

Kim, Hyeong Seok; Han, Youngmin; Kang, Jae Seung; et al. Ann Surg. 2022 Oct 1;276(4):e231-e238.


12. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma.

13. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma.


15. Immunophenotypic and molecular characterization of pancreatic neuroendocrine tumors producing serotonin.


19. The diagnostic and prognostic utility of incorporating DAXX, ATRX, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.
Heaphy CM, Singhi AD. Hum Pathol. 2022 Nov;129:11-20.

20. Problems and solutions: a special issue of gastrointestinal, pancreatic, and liver pathology.
Torbenson M, Erickson LA. Hum Pathol. 2022 Nov;129:56-59.
21. SUOX and GLUT1 are biomarkers for the prognosis in large duct type intrahepatic cholangiocarcinoma.


23. Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma.

Journal Watch Team (in alphabetical order):

1. Dr. Daniela Allende (Editor), Cleveland Clinic.
2. Dr. Deyali Chatterjee, The University of Texas MD Anderson Cancer Center.
3. Dr. Wei Chen, The Ohio State University.
4. Dr. Deepti Dhall, University of Alabama at Birmingham.
5. Dr. Eva Karamitopoulou, Universität Bern Institut für Pathologie.
6. Dr. Claudio Luchini, University of Verona.
7. Dr. Ilke Nalbantoglu, Yale University.
8. Dr. Hanlin Wang, UCLA Medical Center.

9. Dr. Yue Xue, Northwestern Memorial Hospital.

**List of journals reviewed:**

1. AJSP
2. Pancreatology
3. Gastroenterology
4. Hepatology
5. Modern Pathology
6. Histopathology
7. Journal of Molecular Diagnostics
8. Virchows Archives
9. Human Pathology
10. Am J Gastroenterol
11. Pancreas
12. Clin Gastroenterol and Hepatol
13. Gut
15. Archives of Pathol and Lab Med
16. Seminars in Diagnostic Pathology
17. Cancer Cytopathology
18. Journal of American Society of Cytopathology
19. Diagnostic Cytopathology
20. Annals of Surgical Oncology
21. Annals of Surgery
22. Endocrine Pathology
23. Cancer
24. International Journal of Surgical Pathology
25. Generic organ specific searches